Articles tagged with Inflammatory Response
Researchers from Case Western Reserve University found that blocking receptors responding to bacterial infections can nearly halve preterm deaths in mice. A synthetic TLR4 antagonist appears safe for mice mothers and pups.
Penn researchers identified how regulatory protein Bcl-3 regulates inflammation by blocking ubiquitination, a critical biochemical process. This discovery opens new avenues for developing therapies to treat infectious or inflammatory diseases such as sepsis and rheumatoid arthritis.
Dutch researchers have developed a DNA layer that improves attachment, recovery, and immune response to body implants. The coating, patented by Jeroen van den Beucken, approximates the body's natural material, reducing inflammation and immune responses.
A recent study suggests that parasite infection may alter the course of multiple sclerosis (MS) by affecting the immune response. MS patients with a parasite infection showed fewer clinical relapses and less disability compared to uninfected controls.
Researchers found that a gene for an anti-insect enzyme is up to 250 times more active in people with severe sinus inflammation. The enzyme's presence was linked to chronic sinusitis, which affects an estimated 32 million Americans.
A study by Emory University researchers found that depressed patients exhibit an exaggerated inflammatory response to psychological stress compared to healthy individuals. The study suggests a potential link between depression and other diseases, including heart disease.
A recent editorial in The Lancet suggests that asthma may not be a single disease entity but rather a collection of symptoms with varying triggers and responses. This conclusion is based on the lack of understanding about what triggers inflammation in the airways, leading to the condition.
Research suggests that pregnant women with periodontitis have higher CRP levels, which may contribute to preeclampsia and preterm delivery. The study's findings support previous research linking periodontal disease and inflammation with adverse pregnancy outcomes.
Researchers found that IL-25 promotes type 2 responses driving asthma, but also limits destructive inflammation associated with inflammatory bowel disease. The study suggests IL-25 may offer a treatment avenue for chronic inflammatory diseases.
The study found that Nrf2 plays a crucial role in regulating the body's inflammatory response and protecting against oxidative stress. Mice deficient in Nrf2 expressed increased levels of cytokines, leading to early death in sepsis cases, highlighting its potential as a therapeutic target.
Researchers found that isolated female rats subjected to a 30-minute stressor recover more quickly and mount a stronger immune response than male counterparts. This difference may be related to the demands of motherhood, which has evolved to provide females with protection against trauma.
Researchers found that the Runx1 gene is essential for the development and function of nociceptive sensory neurons, which are responsible for sensing pain. The study reveals that Runx1 regulates the specification of these neurons and their wiring, providing a genetic basis for chronic pain.
Researchers discover a novel proton-sensing G-protein coupled receptor that operates normally in acidic conditions, indicating potential new therapeutic avenues for arthritis, heart attacks, and strokes. The receptor's optimal function is at pH6.4, suggesting its role in synovial inflammation and cell proliferation.
Researchers identify how nuclear receptors work to suppress inflammatory responses, potentially leading to more powerful anti-inflammatory drugs with fewer side effects. This discovery could lead to better therapeutic results in treating diseases such as arthritis and arteriosclerosis.
Researchers analyzed the expression levels of genes in circulating white blood cells after injection with bacterial endotoxin, identifying novel pathways and associations with inflammatory processes. The findings aim to improve trauma treatment by tailoring treatments to patients' individual needs.
Researchers tracked gene activity in response to bacterial endotoxin, identifying molecular markers for sepsis. The study found that more than half of genes involved in inflammation were turned down, contrary to expected responses.
Researchers are investigating a drug that may block the deadliest form of inflammation in heart bypass patients, including those who have had previous strokes or heart attacks. The study focuses on high-risk patients and pediatric cases, aiming to improve outcomes and reduce morbidity related to heart surgery.
Patients undergoing laparoscopic surgery had lower levels of inflammatory markers CRP and IL-6 compared to conventional surgery. The levels of natural killer cells were also significantly higher in laparoscopic surgery patients.
Annexin 1 gene expression plays a critical protective role in preventing immune damage during sepsis, with higher levels associated with organ injury and lower survival rates. Administration of human recombinant annexin 1 improved survival rates to 60%.
UCSD medical researchers show that a protein called I-kappa-B kinase alpha (IKKa) is responsible for terminating an inflammatory response before it can damage cells and organs. IKKa's mechanism involves interacting with proteins RelA and C-Rel, which bind to genes mediating the inflammatory response for a short duration.
Researchers from Imperial College London identified an enzyme called IKKá, which acts as a 'brake' on immune cell pathways. By inhibiting IKKa activity, the body's ability to fight off infection increased, but also led to higher inflammatory responses.
Researchers created a genomic analysis tool to study critically ill patients, enabling physicians to predict treatment responses and develop new therapeutic strategies. The technology allows for the detection of significant gene activity differences between trauma patients and healthy individuals.
Research reveals NOD2 activation leads to modification of NEMO, a central component of the NF-kB signaling pathway controlling inflammatory responses. This discovery suggests a potential pharmacological target for Crohn's Disease treatment.
Researchers at the Salk Institute have discovered a critical component of the complex that enables NF-kB to trigger inflammatory responses. The study identifies ELKS protein as essential for NF-kB's function, opening new avenues for treating autoimmune diseases like lupus and arthritis.
A new study published in the Journal of Clinical Investigation has identified an antagonistic antibody that can prevent sepsis by blocking toll-like receptor 2-driven shock-like syndromes. The discovery offers new hope for combating this deadly condition.
A Cincinnati Children's Hospital study found a deficiency in lipoxins, key regulators of inflammation, in children with cystic fibrosis. This discovery provides impetus for developing novel therapeutics to decrease lung inflammation.
Researchers discovered a link between serum amyloid alpha (SAA) and future cardiovascular events, with increased levels predicting a 3% higher risk of heart attack or stroke over three years. SAA appears to respond specifically to active heart disease, making it a potential more accurate predictor than C-reactive protein.
Dr. Peter Ward, a renowned U-M pathologist, has received the American Thoracic Society's highest honor for his pioneering research on inflammation and lung biology. His work has significantly broadened the understanding of lung health and disease, influencing the career development of many clinicians and scientists worldwide.
Scientists at UCSD discovered a protein, HIF-1, that enables white blood cells to function in low-oxygen environments, leading to inflammation. Inhibiting this protein blocks inflammatory responses in mice, offering new hope for treating arthritis and potentially improving cancer treatment.
Researchers at Zengen discovered that synthetic alpha-Melanocyte-Stimulating Hormone (a-MSH) has an anti-inflammatory effect in celiac mucosa, which may control the inflammatory response and limit epithelial damage. This finding could lead to a medical treatment for Celiac disease, currently managed only with a strict gluten-free diet.
A national effort is underway to study traumatic injury and develop evidence-based treatments. The project will compile extensive databases and standardize care procedures to help physicians choose the best treatment for each patient.
Research suggests that PGE2 can alleviate intestinal inflammation by inhibiting NF-\u00b8B and JAK/STAT pathways. Additionally, the study highlights the importance of targeting PGE2 receptors in the treatment of inflammatory bowel disease.
Researchers found that nicotine withdrawal causes inflammation and similar biochemical responses as acute or chronic illnesses, potentially leading to depression, fatigue, muscle aches, and appetite changes. Anti-inflammatory treatments may alleviate these symptoms, increasing the likelihood of successful quitting.
Johns Hopkins researchers have identified a protein called stat3-beta that regulates genes involved in systemic inflammation. In mice engineered to lack this protein, researchers found fatal kidney failure due to uncontrolled inflammation, highlighting the potential of stat3-beta as a therapeutic target for human inflammatory diseases.
A study by Stock et al. reveals that genetic disruption of the PGE2 receptor EP1 significantly reduces pain behavior and blood pressure responses to inflammation. The findings suggest that NSAID treatment's analgesic effect can be explained by inhibition of signaling through this single receptor type.
HHMI researchers have found a way to shut down the inflammatory response in cells that spares related mechanisms needed for proper function. The treatment relieves inflammation in mice with surprising effectiveness by targeting NF-kB.
Researchers at Emory University Health Sciences Center discovered that non-pathogenic bacteria in the GI tract can block an immune system pathway called NF-KB, preventing cells from responding to potential threats. This mechanism may play a crucial role in the pathogenesis of inflammatory bowel disease and other intestinal diseases.
A recent study found that high levels of inflammation can impede the effectiveness of clot-busting treatment after a heart attack. Individuals with elevated C-reactive protein levels had slower responses to thrombolytic therapy, resulting in delayed revascularization and increased damage to the heart.
Researchers have discovered a new class of synthetic molecules that effectively inhibit inflammation by removing L-selectin proteins from the cell surface, preventing cells from sticking together. This approach offers a novel strategy for treating pain and swelling associated with injury or illness.